Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Prostate Cancer Metastatic
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Apr 2024, none posted yet
Counts until it's fixed
- +1.4
5 insiders sold shares within a month
Since May 21, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 248 (final count)
- Started
- Mar 1, 2019
- Main results expected
- Apr 29, 2024
- Fully finished
- Jan 27, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Incidence of Dose Limiting Toxicities of ARV-110
Measured over: 28 Days
Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-110
Measured over: 28 Days
Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-110
Measured over: 28 Days
Part B: Measurement of PSA response rate per PCWG3 accessing anti-tumor activity of ARV-110
Measured over: 12 Weeks
Part B: Measurement of overall RECIST response rate accessing the anti-tumor activity of ARV-110
Measured over: 12 Weeks
Part B: To evaluate the clinical anti-tumor activity of ARV-110 in patients with mCRPC
Measured over: 12 Weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-04-29, no fading
- insider_selling_cluster: base 10, now 1.4, since 2026-05-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03888612 · record last updated 2025-04-01 · checked 2026-11-09 15:47 UTC